Cutaneous T-Cell Lymphoma Pipeline Analysis Shows a Tremendous Growth Opportunities for the Upcoming Years in the Domain
“Cutaneous T-Cell Lymphoma Pipeline”
DelveInsight’s Cutaneous T-Cell Lymphoma (CTCL) pipeline report gives extensive insights into the Cutaneous T-Cell Lymphoma (CTCL) pipeline environment, including 50+ companies and 50+ pipeline drugs. It also includes clinical and nonclinical stage products in the pipeline drug profiles.
DelveInsight’s Cutaneous T-Cell Lymphoma (CTCL) pipeline report gives extensive insights into the Cutaneous T-Cell Lymphoma (CTCL) pipeline environment, including 50+ companies and 50+ pipeline drugs. It also includes clinical and nonclinical stage products in the pipeline drug profiles.
Some of the Important Highlights from the Cutaneous T-Cell Lymphoma Pipeline Report
There are currently 50+ drugs in the pipeline for the treatment of Cutaneous T-Cell Lymphoma.
Cutaneous T-Cell Lymphoma pipeline comprises therapies which are in different stages of clinical phase include Naloxone Hydrochloride Lotion, SGX301, Atezolizumab, Pembrolizumab, ASTX 660, Durvalumab, LB1901, Tinostamustine and others and are expected to get available in the upcoming years.
Key pharmaceutical players which are testing their drug candidates for CTCL treatment include Elorac, Soligenix, Hoffmann-La Roche, Merck Sharp & Dohme Corp, Otsuka Pharmaceutical Co., Ltd, AstraZeneca, Legend Biotech USA Inc, Mundipharma-EDO GmbH, among others.
Soligenix, Inc. announced in January 2021 that it had signed an exclusive Supply, Distribution, and Services Agreement with Daavlin. The regulatory and commercial strategy for SGX301 (synthetic hypericin) for the treatment of Cutaneous T-Cell Lymphoma includes ensuring long-term supply and distribution of a commercially ready light device.
Soligenix announced in April 2020 that the European Patent Office had granted the divisional patent application titled “Formulations and Methods of Treating Skin Conditions.” The granted claims concern the therapeutic application of synthetic hypericin in the treatment of Cutaneous T-Cell Lymphoma.
Apart from SGX301, Naloxone Hydrochloride Lotion which is developed by Elorac is in Phase III of development for CTCL treatment.
To get an overview, what does cutaneous t-cell lymphoma looks like, request sample @ Cutaneous T-Cell Lymphoma Types
Cutaneous T-Cell Lymphoma: Overview
Cutaneous T-Cell Lymphoma (CTCL) is a rare type of cancer that begins in T cells (T lymphocytes), which are white blood cells. Normally, these cells assist your body’s immune system in fighting germs. T cells in Cutaneous T-Cell Lymphoma develop abnormalities that cause them to attack the skin.
There are two subtypes of Cutaneous T-Cell Lymphoma: Mycosis Fungoides (MF) and Sézary Syndrome
Cutaneous T-Cell Lymphoma Symptoms
Dry skin, itching (which can be severe), a red rash, and swollen lymph nodes are all symptoms of Cutaneous T-Cell Lymphoma. Men are more likely to get affected by the disease than women. It typically strikes men in their 40s, 50s, and 60s. The majority of CTCL patients experience only skin symptoms.
Cutaneous T-Cell Lymphoma Treatment
The level of skin involvement, the type of skin lesion, and whether the cancer has spread to the lymph nodes or other internal organs are all aspects taken into account when determining the best treatment for each patient.
Cutaneous T-Cell Lymphoma Pipeline Analysis: Drug Profiles
SGX301: Soligenix
Product Description
SGX301 (synthetic hypericin) is a revolutionary, first-in-class photodynamic treatment that activates cells with safe visible light. Synthetic hypericin, the active ingredient in SGX301, is a powerful photosensitizer that is administered topically to skin lesions, taken up by malignant T-cells, and then triggered by fluorescent light 16 to 24 hours later.
Phase III
NCT02448381: Soligenix began a Phase 3 multicenter, randomised, double-blind, placebo-controlled research in December 2015 to see if topical SGX301 (Synthetic Hypericin) and fluorescent bulb-light irradiation for the treatment of Cutaneous T-Cell Lymphoma were effective.
For more information on the emerging drugs and companies, visit Cutaneous T-Cell Lymphoma Pipeline Analysis
Cutaneous T-Cell Lymphoma Pipeline Therapies and Key Companies
Elorac: Naloxone Hydrochloride Lotion
SGX301: Soligenix
Atezolizumab: Hoffmann-La Roche
Pembrolizumab: Merck Sharp & Dohme Corp
ASTX 660: Otsuka Pharmaceutical Co., Ltd
Durvalumab: AstraZeneca
LB1901: Legend Biotech USA Inc
Tinostamustine: Mundipharma-EDO GmbH
Cutaneous T-Cell Lymphoma Therapeutics Assessment
By Product Type
Monotherapy
Combination Therapy
By Stage
Discovery
Pre-Clinical
Phase I
Phase II
Phase III
Pre-registration
By Route of Administration
Inhalation
Intravenous
Oral
Subcutaneous
By Molecule Type
Small Molecule
Stem Cell Therapy
Gene Therapy
Targets
Immune System
Multiple Kinase
By Mechanism of Action
Protease Inhibitors
Immunomodulatory
Scope of the Report
Coverage: Global
Cutaneous T-Cell Lymphoma Key Players: Elorac, Soligenix, Hoffmann-La Roche, Merck Sharp & Dohme Corp, Otsuka Pharmaceutical Co., Ltd, AstraZeneca, Legend Biotech USA Inc, Mundipharma-EDO GmbH,among others
Cutaneous T-Cell Lymphoma Pipeline Therapies: Naloxone Hydrochloride Lotion, SGX301, Atezolizumab, Pembrolizumab, ASTX 660, Durvalumab, LB1901, Tinostamustine, and others
Table of Contents
1.
Introduction
2.
Executive Summary
3.
Cutaneous T-Cell Lymphoma : Overview
4.
Cutaneous T-Cell Lymphoma – Analytical Perspective In-depth Commercial Assessment
5.
Cutaneous T-Cell Lymphoma Pipeline Therapeutics
6.
Cutaneous T-Cell Lymphoma Late Stage Products (III)
7.
Cutaneous T-Cell Lymphoma Mid Stage Products (Phase II)
8.
Cutaneous T-Cell Lymphoma Early Stage Products (Phase I)
9.
Cutaneous T-Cell Lymphoma Therapeutic Assessment
10.
Cutaneous T-Cell Lymphoma Inactive Products
11.
Cutaneous T-Cell Lymphoma Company-University Collaborations (Licensing/Partnering) Analysis
12.
Cutaneous T-Cell Lymphoma – Key Companies
13.
Cutaneous T-Cell Lymphoma – Key Products
14.
Cutaneous T-Cell Lymphoma – Unmet Needs
15.
Cutaneous T-Cell Lymphoma – Market Drivers and Barriers
16.
Cutaneous T-Cell Lymphoma – Future Perspectives and Conclusion
17.
Cutaneous T-Cell Lymphoma – Analyst Views
18.
Appendix
19.
About DelveInsight
For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare and Biotech Blog Posts
Key questions answered in the Cutaneous T-Cell Lymphoma Pipeline Report
What therapy options are available for Cutaneous T-Cell Lymphoma?
How many drug companies are developing treatments for Cutaneous T-Cell Lymphoma?
Which of these companies’ drugs are the most popular?
What is the total number of Cutaneous T-Cell Lymphoma medicines produced by each company?
How many medications in the Cutaneous T-Cell Lymphoma pipeline are in the early stages of development, the mid stages of development, or the late stages of development?
How many of the therapies in development can be used on their own or in combination with other treatments?
What are the most significant industry-industry and industry-academy collaborations, mergers & acquisitions, and licencing practises affecting Cutaneous T-Cell Lymphoma?
Related Reports
Peripheral T-Cell Lymphoma Pipeline Insights
Get comprehensive analysis of Pruritus pipeline therapies and key companies including Acrotech Biopharma LLC, Seattle Genetics, Inc., CerRx, Inc., Verastem, Inc., Kura Oncology, Inc., among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.
About Senmer News Wire
Senmer News Wire supplies premium & affordable press release publishing service from 2013, and has served thousands of clients. New service – PBN posts, Quora Answers, Yahoo Answers, High DA Profiles Backlinks, Directory Submission Service, Local Citations Service
Source: Cutaneous T-Cell Lymphoma Pipeline Analysis Shows a Tremendous Growth Opportunities for the Upcoming Years in the Domain
Comments
Post a Comment